Teva (TEVA) Investors Like CEO Succession Plan, Shares Move Higher
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $12.80 -0.62%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Overall Analyst Rating:
NEUTRAL (= Flat)
Dividend Yield: 2.1%
EPS Growth %: +30.0%
Join SI Premium – FREE
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA),shares are trading about 5 percent better Tuesday, following its CEO succession plans.
Late last Friday, Teva said CEO Shlomo Yanai will retire, and Bristol-Myers Squibb's Dr. Jeremy Levin will assume the role in May 2012.
For more color, click here.
Late last Friday, Teva said CEO Shlomo Yanai will retire, and Bristol-Myers Squibb's Dr. Jeremy Levin will assume the role in May 2012.
For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Whirlpool (WHR) Appoints Roxanne Warner as Corporate Controller
- Claros Mortgage Trust, Inc. (CMTG) Announces Resignation of Kevin Cullinan, EVP of Originations
- The Arena Group Holdings (AREN) Appoints Sara Silverstein as CEO
Create E-mail Alert Related Categories
Insiders' Blog, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
